Headlines about Can Fite Biopharma (NASDAQ:CANF) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Can Fite Biopharma earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.4409293900727 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of equities analysts recently commented on CANF shares. Maxim Group reiterated a “buy” rating and issued a $7.00 target price on shares of Can Fite Biopharma in a research report on Monday, September 18th. HC Wainwright set a $6.00 target price on shares of Can Fite Biopharma and gave the stock a “buy” rating in a research report on Thursday, August 10th.
Can Fite Biopharma (CANF) opened at 1.6799 on Monday. The stock’s market cap is $29.17 million. The company has a 50-day moving average of $1.69 and a 200-day moving average of $1.78. Can Fite Biopharma has a 12 month low of $1.50 and a 12 month high of $2.67.
Can Fite Biopharma Company Profile
Can Fite Biofarma Ltd is an Israel-based biopharmaceutical company. The Company develops new treatments for autoimmune diseases and cancer. The Company’s drugs are CF101 for Psoriasis treatment, RA treatment, for the treatment of Keratoconjunctictivitis Sicca, for the treatment of Glaucoma, among others; and CF102 for the treatment of liver diseases.